


**Product Name** : OC000459  
**Cat. No.** : PC-38844  
**CAS No.** : 851723-84-7  
**Molecular Formula** : C<sub>21</sub>H<sub>17</sub>FN<sub>2</sub>O<sub>2</sub>  
**Molecular Weight** : 348.377  
**Target** : Prostaglandin Receptor  
**Solubility** : 10 mM in DMSO



## Biological Activity

OC000459 is a potent, selective, and orally active D prostanoid receptor 2 (DP2, CRTH2) antagonist with K<sub>i</sub> of 13/3 nM for human/recombinant DP2, respectively.

OC000459 does not interfere with the ligand binding properties or functional activities of other prostanoid receptors (prostaglandin E1-4 receptors, D1, thromboxane receptor, prostacyclin receptor, and prostaglandin F receptor).

OC000459 inhibited chemotaxis (IC<sub>50</sub>= 28 nM) of human Th2 lymphocytes and cytokine production (IC<sub>50</sub>=19 nM) by human Th2 lymphocytes.

OC000459 competitively antagonized eosinophil shape change responses induced by PGD<sub>2</sub> in both isolated human leukocytes (pK(B)=7.9) and human whole blood (pK(B)=7.5) but did not inhibit responses to eotaxin, 5-oxo-eicosatetraenoic acid, or complement component C5a.

OC000459 is orally bioavailable in rats and effective in inhibiting blood eosinophilia induced by 13,14-dihydro-15-keto-PGD<sub>2</sub> (DK-PGD<sub>2</sub>) with ED<sub>50</sub> of 0.04 mg/kg (p.o.) and airway eosinophilia in response to an aerosol of DK-PGD<sub>2</sub> in guinea pigs (ED<sub>50</sub>=0.01 mg/kg p.o.).

## References

Pettipher R, et al. J Pharmacol Exp Ther. 2012 Feb;340(2):473-82.

Barnes N, et al. Clin Exp Allergy. 2012 Jan;42(1):38-48.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com